Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis
Leila Gobejishvili,Walter E Rodriguez,Philip Bauer,Yali Wang,Chirag Soni,Todd Lydic,Shirish Barve,Craig McClain,Claudio Maldonado
DOI: https://doi.org/10.2147/DDDT.S355796
2022-05-03
Abstract:Leila Gobejishvili, 1 Walter E Rodriguez, 1 Philip Bauer, 2 Yali Wang, 1 Chirag Soni, 2 Todd Lydic, 3 Shirish Barve, 1 Craig McClain, 1 Claudio Maldonado 4 1 Department of Medicine, School of Medicine, University of Louisville, Louisville, KY, USA; 2 Endoprotech, Inc., Louisville, KY, USA; 3 Lipidomics Center, Michigan State University, East Lansing, MI, USA; 4 Department of Physiology, School of Medicine, University of Louisville, Louisville, KY, USA Correspondence: Claudio Maldonado, Department of Physiology, School of Medicine, University of Louisville, 500 S. Preston Street, HSC A-1115, Louisville, KY, 40292, USA, Tel +1 (502) 852-1078, Email Leila Gobejishvili, Department of Medicine, School of Medicine, University of Louisville, 505 S. Hancock Street, CTR 516, Louisville, KY, 40202, USA, Tel +1 (502) 852-0361, Fax +1 (502) 852-8927, Email Introduction: The phosphodiesterase 4 (PDE4) inhibitor, rolipram, has beneficial effects on tissue inflammation, injury and fibrosis, including in the liver. Since rolipram elicits significant CNS side-effects in humans (ie, nausea and emesis), our group developed a fusogenic lipid vesicle (FLV) drug delivery system that targets the liver to avoid adverse events. We evaluated whether this novel liposomal rolipram formulation reduces emesis. Methods: C57Bl/6J male mice were used to compare the effect of three doses of free and FLV-delivered (FLVs-Rol) rolipram in a behavioral correlate model of rolipram-induced emesis. Tissue rolipram and rolipram metabolite levels were measured using LC-MS/MS. The effect of FLVs-Rol on brain and liver PDE4 activities was evaluated. Results: Low and moderate doses of free rolipram significantly reduced anesthesia duration, while the same doses of FLVs-Rol had no effect. However, the onset and duration of adverse effects (shortening of anesthesia period) elicited by a high dose of rolipram was not ameliorated by FLVs-Rol. Post-mortem analysis of brain and liver tissues demonstrated that FLVs affected the rate of rolipram uptake by liver and brain. Lastly, administration of a moderate dose of FLVs-Rol attenuated endotoxin induced PDE4 activity in the liver with negligible effect on the brain. Discussion: The findings that the low and moderate doses of FLVs-Rol did not shorten the anesthesia duration time suggest that FLV delivery prevented critical levels of drug from crossing the blood-brain barrier (BBB) to elicit CNS side-effects. However, the inability of high dose FLVs-Rol to prevent CNS side-effects indicates that there was sufficient unencapsulated rolipram to cross the BBB and shorten anesthesia duration. Notably, a moderate dose of FLVs-Rol was able to decrease PDE4 activity in the liver without affecting the brain. Taken together, FLVs-Rol has a strong potential for clinical application for the treatment of liver disease without side effects. Keywords: liposomes, rolipram, side-effects, PDE4, liver Chronic liver disease is a significant health problem worldwide and has a high mortality. Alcohol associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are among the major causes of chronic liver disease. 1–3 Experimental studies have provided a rationale for targeting phosphodiesterase 4 (PDE4) as a therapeutic strategy for liver disease, including for ALD and NAFLD. 4–6 PDE4 inhibitors have been shown to be effective in reducing inflammation, injury and fibrosis in the liver in animal studies. 7–12 However, the clinical application of PDE4 inhibitors, such as rolipram, is hampered by dose-associated side-effects, including severe nausea and emesis caused by increased cyclic adenosine monophosphate (cAMP) levels in the central nervous system (CNS). 13,14 Rolipram, which is lipophilic, easily crosses the blood-brain barrier (BBB) 15 and is able to inhibit PDE4 in the emetic centers of the brainstem, 16 causing nausea and emesis. To ameliorate the nausea and emetic response accompanied by systemic rolipram administration, our group developed a nanoliposome-based fusogenic lipid vesicle (FLV) system for rolipram delivery (FLVs-Rol). The FLV carrier system was designed to target rolipram to hepatic tissue, and at the same time, to restrict levels of free drug from circulating in the blood and, thus, impede its crossing of the BBB. Bio-distribution studies of FLVs without drug documented the major uptake of FLVs by the liver in mice. 10 Importantly, previous work demonstrated that FLV delivery of rolipram was very effective in attenuating hepatic injury in a mouse model of ALD. 10 Examining rolipram-induced side effects -Abstract Truncated-